DelveInsight’s “Hand Eczema Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Hand Eczema, historical and forecasted epidemiology as well as the Hand Eczema market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Hand Eczema market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Hand Eczema Market Forecast
Some of the key facts of the Hand Eczema Market Report:
- The Hand Eczema market size was valued ~USD 11 billion in 2021 and is anticipated to grow with a significant CAGR during the study period (2019-2032)
- According to projections, there would be over 63 million cases of hand eczema widespread in the 7MM by 2021
- The US experienced the biggest number of Hand eczema cases in 2021—roughly 26,000,000—while Spain experienced the lowest number—roughly 4,000,000
- Hand eczema afflicted roughly 11,000,000 men and 16,000,000 women in the United States in 2021, and it is predicted that prevalence will rise and reach up to 11,555,000 men and 16,800,000 women, respectively, by 2032
- Germany has the most Hand Eczema cases (more than 7,000,00 cases) among the EU4 and the UK in 2021
- Key Hand Eczema Companies: Leo Pharma, Japan Tobacco Inc., Asana Biosciences, Regeneron, Sanofi, Incyte Corporation, ACO Hud Nordic AB, LEO Pharma, Arcutis Biotherapeutics, Inc., Basilea Pharmaceutica, Novartis, and others
- Key Hand Eczema Therapies: Delgocitinib, ASN002 (Gusacitinib), Dupilumab, Ruxolitinib cream, betamethasone valerate, LEO 124249, ARQ-252, alitretinoin, Pimecrolimus, and others
- The Hand Eczema epidemiology based on gender analyzed that Hand eczema is more prevalent in females as compared to males
- The Hand Eczema market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Hand Eczema pipeline products will significantly revolutionize the Hand Eczema market dynamics.
Hand Eczema Overview
One of the most typical varieties of eczema and one of the most prevalent skin illnesses globally is hand dermatitis, sometimes referred to as hand eczema. Although it can affect other regions of the hand, it primarily affects the palms. Hand eczema can range in severity from extremely minor to severe, and its course can be either acute or chronic, causing long-term impairment.
Get a Free sample for the Hand Eczema Market Report
https://www.delveinsight.com/report-store/hand-eczema-market
Hand Eczema Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Hand Eczema Epidemiology Segmentation:
The Hand Eczema market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
- Total Prevalence of Hand Eczema
- Prevalent Cases of Hand Eczema by severity
- Gender-specific Prevalence of Hand Eczema
- Diagnosed Cases of Episodic and Chronic Hand Eczema
Download the report to understand which factors are driving Hand Eczema epidemiology trends @ Hand Eczema Epidemiology Forecast
Hand Eczema Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Hand Eczema market or expected to get launched during the study period. The analysis covers Hand Eczema market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Hand Eczema Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Hand Eczema Therapies and Key Companies
- Delgocitinib: Leo Pharma/ Japan Tobacco Inc.
- ASN002 (Gusacitinib): Asana Biosciences
- Dupilumab: Regeneron/Sanofi
- Ruxolitinib cream: Incyte Corporation
- betamethasone valerate: ACO Hud Nordic AB
- LEO 124249: LEO Pharma
- ARQ-252: Arcutis Biotherapeutics, Inc.
- alitretinoin: Basilea Pharmaceutica
- Pimecrolimus: Novartis
Discover more about therapies set to grab major Hand Eczema market share @ Hand Eczema Treatment Market
Hand Eczema Market Strengths
- Widespread prevalence of the disease.
- Development of disease-specific treatments and novel therapeutic drug classes such as JAK inhibitors is likely to boost the market growth.
Hand Eczema Market Opportunities
- The emerging drugs have a significant opportunity, as there are no disease-specific approved therapies for the treatment of hand eczema in the US
- The current management of the disease includes only symptomatic treatments and does not treat the underlying cause of the disease.
Scope of the Hand Eczema Market Report
- Study Period: 2019–2032
- Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
- Key Hand Eczema Companies: Leo Pharma, Japan Tobacco Inc., Asana Biosciences, Regeneron, Sanofi, Incyte Corporation, ACO Hud Nordic AB, LEO Pharma, Arcutis Biotherapeutics, Inc., Basilea Pharmaceutica, Novartis, and others
- Key Hand Eczema Therapies: Delgocitinib, ASN002 (Gusacitinib), Dupilumab, Ruxolitinib cream, betamethasone valerate, LEO 124249, ARQ-252, alitretinoin, Pimecrolimus, and others
- Hand Eczema Therapeutic Assessment: Hand Eczema current marketed and Hand Eczema emerging therapies
- Hand Eczema Market Dynamics: Hand Eczema market drivers and Hand Eczema market barriers
- Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
- Hand Eczema Unmet Needs, KOL’s views, Analyst’s views, Hand Eczema Market Access and Reimbursement
To know more about Hand Eczema companies working in the treatment market, visit @ Hand Eczema Clinical Trials and Therapeutic Assessment
Table of Contents
1. Hand Eczema Market Report Introduction
2. Executive Summary for Hand Eczema
3. SWOT analysis of Hand Eczema
4. Hand Eczema Patient Share (%) Overview at a Glance
5. Hand Eczema Market Overview at a Glance
6. Hand Eczema Disease Background and Overview
7. Hand Eczema Epidemiology and Patient Population
8. Country-Specific Patient Population of Hand Eczema
9. Hand Eczema Current Treatment and Medical Practices
10. Hand Eczema Unmet Needs
11. Hand Eczema Emerging Therapies
12. Hand Eczema Market Outlook
13. Country-Wise Hand Eczema Market Analysis (2019–2032)
14. Hand Eczema Market Access and Reimbursement of Therapies
15. Hand Eczema Market Drivers
16. Hand Eczema Market Barriers
17. Hand Eczema Appendix
18. Hand Eczema Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services